Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eftrenonacog alfa
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Eftrenonacog alfa is a long-acting recombinant fusion protein used for the treatment and prevention of bleeding in patients with hemophilia B (congenital factor IX deficiency). It consists of a single molecule of human coagulation factor IX covalently linked to the Fc domain of human immunoglobulin G1 (IgG1) via recombinant DNA technology. The Fc domain extends the half-life by binding to the neonatal Fc receptor (FcRn), which protects it from lysosomal degradation and recycles it back into circulation, resulting in prolonged therapeutic action. Eftrenonacog alfa serves as replacement therapy to increase plasma levels of factor IX, temporarily correcting deficiency and enabling normal blood clotting. It is indicated for prophylaxis, control of acute bleeding episodes, and perioperative management in patients with hemophilia B[1][2][3][4][5][6].
- Brand names
- Alprolix
- Other names
- recombinant human coagulation factor IX Fc fusion proteinrFIXFc
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)F9 (Coagulation Factor IX)
Beyond the preview
Go deeper on eftrenonacog alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eftrenonacog alfa.